Actinogen Medical Ltd has released a press release.
Actinogen FY22 Results - Accelerating Clinical Development
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW Appendix 4E and 2022 Annual Report
- ACW CEO presentation to Spark Plus Aust Equities Day
- Application for quotation of securities - ACW
- ACW announces Phase 2 trial designs for AD & MDD
- Actinogen trial results & strategic update presentation
Later from Actinogen Medical
- ACW announces positive Alzheimers Disease clinical results
- ACW clinical biomarker study webcast presentation
- R&D tax incentive rebate received
- First patient treated in XanaCIDD Phase 2 Depression Trial
- FDA agrees to six-month Phase 2b Alzheimers Disease Trial
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical